We are live on ! Find out more
MG

Meditor Group Portfolio holdings

AUM $48.1M
1-Year Est. Return 38.67%
This Fund
S&P 500
This Quarter Est. Return
-17.96%
1 Year Est. Return
+38.67%
3 Year Est. Return
+41.15%
5 Year Est. Return
+72.2%
10 Year Est. Return
+1,065.64%
AUM
$283M
AUM Growth
-$73.4M
Cap. Flow
-$9.63M
Cap. Flow %
-3.41%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
1
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$3.35M

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 90.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.9B
$195M 69.1%
10,719,400
-556,471
-5% -$13M
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$59.6M 21.09%
2,818,835
+139,000
+5% +$3.35M
INDA icon
3
iShares MSCI India ETF
INDA
$6.71B
$14.2M 5.01%
320,000
– –
EPI icon
4
WisdomTree India Earnings Fund ETF
EPI
$2.02B
$13.5M 4.79%
400,000
– –

Similar funds

BHCM
Boulder Hill Capital Management New York $47.9M AUM
VMV
Venrock Management VI Palo Alto, California $47.6M AUM 45.26% 1-Year Est. Return
BHH
Baker Hughes Holdings Houston, Texas $47.6M AUM 26.35% 1-Year Est. Return
LAMC
Lubert-Adler Management Company Philadelphia, Pennsylvania $49.3M AUM 17.46% 1-Year Est. Return
MAM
Miria Asset Management St. Julians, Malta $49.9M AUM 21.84% 1-Year Est. Return
BCM
BlueMar Capital Management Miami, Florida $49.9M AUM 28.76% 1-Year Est. Return
LOF
Lightspeed Opportunity Fund Menlo Park, California $50.1M AUM 53.1% 1-Year Est. Return
CLCM
Center Lake Capital Management West Palm Beach, Florida $45.8M AUM 58.23% 1-Year Est. Return

Meditor Group's Q2 2021 Portfolio in Review

As of Q2 2021, Meditor Group held 4 positions worth $283M, down 21% from $356M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Meditor Group withdrew a net $9.63M in Q2 2021, reducing 1 holding. Its largest reduction was Exelixis, cutting an estimated $13M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier.

Against the trend, Meditor Group added an estimated $3.35M to Esperion Therapeutics.

  • Meditor Group added most to Esperion Therapeutics in Q2 2021, an estimated $3.35M increase.
  • Meditor Group's biggest Q2 2021 reduction was Exelixis, cutting an estimated $13M.
  • Meditor Group's ten largest holdings make up 100% of its $283M portfolio in Q2 2021.
  • Meditor Group opened 0 new positions and closed 0 in Q2 2021.
  • Meditor Group's portfolio value fell 21% quarter-over-quarter to $283M.

Based on Meditor Group's 13F filing for Q2 2021, filed 12 Jul 2021.